MAPK3 and colorectal cancer: Preclinical evaluation of novel FASN inhibitors in primary colorectal cancer cells (CRCs) and a patient-derived xenograft model of colorectal cancer showed that anti-tumor activity was primary due to a significant decrease in the activation of Akt and Erk1/2 oncogenic pathways in CRCs [102].